AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Bolt Biotherapeutics, Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00N8MY5W8
6.27▲ 2.08 (49.64%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
4.19
Day's Range
5.99 – 7.78
52-Week Range
3.10 – 7.78
Volume
12.7M
Avg Volume
454.1K
Share Statistics
Shares Outstanding
Employees
23
Exchange
XNAS
Listed
2021-02-05
Share count as of August 4, 2026

Bolt Biotherapeutics, Inc. Common Stock (BOLT) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Bolt Biotherapeutics, Inc. Common Stock (BOLT)
What is Bolt Biotherapeutics, Inc. Common Stock's Market Cap?
Bolt Biotherapeutics, Inc. Common Stock's Market Cap is $12.1M, based on as-reported figures from SEC (XBRL) filings.
What is Bolt Biotherapeutics, Inc. Common Stock's Enterprise Value?
Bolt Biotherapeutics, Inc. Common Stock's Enterprise Value is -$5.5M, based on as-reported figures from SEC (XBRL) filings.
What is Bolt Biotherapeutics, Inc. Common Stock's Price / Sales?
Bolt Biotherapeutics, Inc. Common Stock's Price / Sales is 2.6×, based on as-reported figures from SEC (XBRL) filings.
What is Bolt Biotherapeutics, Inc. Common Stock's EV / Revenue?
Bolt Biotherapeutics, Inc. Common Stock's EV / Revenue is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Bolt Biotherapeutics, Inc. Common Stock's EV / EBITDA?
Bolt Biotherapeutics, Inc. Common Stock's EV / EBITDA is 0.2×, based on as-reported figures from SEC (XBRL) filings.
What is Bolt Biotherapeutics, Inc. Common Stock's Revenue (TTM)?
Bolt Biotherapeutics, Inc. Common Stock's Revenue (TTM) is $4.7M, based on as-reported figures from SEC (XBRL) filings.
What is Bolt Biotherapeutics, Inc. Common Stock's Net Income (TTM)?
Bolt Biotherapeutics, Inc. Common Stock's Net Income (TTM) is -$28.7M, based on as-reported figures from SEC (XBRL) filings.
What is Bolt Biotherapeutics, Inc. Common Stock's EBITDA?
Bolt Biotherapeutics, Inc. Common Stock's EBITDA is -$29.8M, based on as-reported figures from SEC (XBRL) filings.
What is Bolt Biotherapeutics, Inc. Common Stock's Diluted EPS (TTM)?
Bolt Biotherapeutics, Inc. Common Stock's Diluted EPS (TTM) is -14.92, based on as-reported figures from SEC (XBRL) filings.
What is Bolt Biotherapeutics, Inc. Common Stock's EBITDA Margin?
Bolt Biotherapeutics, Inc. Common Stock's EBITDA Margin is -635.0%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · BOLTAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Collaboration revenue
YoY growth-99.7%-97.9%—+90.1%
Operating expenses:
Research and development
General and administrative
Impairment charges———
Total operating expense
% of revenue167580.0%29334.6%383.4%455.1%
Loss from operations
% of revenue-167480.0%-29234.6%-283.4%-355.1%
Other income (expense), net:
Interest income, net
Other income, net
Total other income (expense), net
Net loss
% of revenue-154400.0%-27861.5%-265.2%-329.4%
Net loss per share, basic
Net loss per share, diluted